Robotic surgery (RS) for colorectal disease was first reported in
There were no significant differences in operation time, length of hospital stay, time to resume regular diet, postoperative morbidity and mortality, and oncological accuracy of resection. 2 Lin et al. also conducted a meta-analysis and reported that RS had favorable outcomes considering conversion compared with LS for rectal cancer. Meanwhile, the following factors were similar between RS and LS: operation time, blood loss, days to passing flatus, length of hospital stay, complications and pathological details, including number of lymph nodes harvested, distal resection margin, and positive circumferential resection margin. 3 Liao et al. identified four randomized controlled studies for metaanalysis. In total, 110 patients underwent colorectal surgery in the RS group and 116 in the LS group. The results revealed that blood loss, conversion rate and time to recovery of bowel function in the RS group were significantly lower than those in the LS group. There were no significant differences in complication rates, length of hospital stay, proximal margins, distal margins and harvested lymph nodes between the two techniques. 4 Based on the review of these meta-analyses, RS for colorectal cancer has a lower conversion rate compared with LS, with no difference in recovery, postoperative and oncological outcomes. In contrast, there are few reports on long-term prognosis of RS for colorectal cancer, although recent survival analysis using propensity score matching shows that the 5-year survival rates of robotic versus laparoscopic resection were 91% versus 78% for overall survival and 73% versus 68% for disease-free survival. 5 The ROLARR trial 6 is a pan-world, prospective, randomized, con- 
